题名

第二型鈉－葡萄糖轉運蛋白抑制劑臨床使用及療效

DOI

10.6666/ClinMed.202008_86(2).0090

作者

胡譯安；黎思源

关键词

第二型鈉－葡萄糖轉運蛋白抑制劑（sodium glucose cotransporter-2 inhibitor） ； 糖尿病（diabetes mellitus） ； 慢性腎病變（chronic kidney disease）

期刊名称

臨床醫學月刊

卷期/出版年月

86卷2期（2020 / 08 / 28）

页次

502 - 504

内容语文

繁體中文
中文摘要

第二型糖尿病是造成慢性腎病及腎臟衰竭的主要原因，但目前只有少數藥物，臨床証實能有效減緩糖尿病腎病變進展，像是阻斷腎素－血管收縮素－醛固酮系統（renin-angiotensin-aldosterone system）的血管張力素轉化酶抑制劑（ACEI），和血管張力素受體阻滯劑（ARB）。第二型鈉－葡萄糖轉運蛋白抑制劑（sodium glucose cotransporter-2 inhibitor, SGLT-2 inhibitor）是近年新發展的降血糖藥物，近期有多個大型臨床試驗，研究該藥物對心血管疾病預後的影響，像是EMPA-REGOUTCOME、CANVAS Program、CVD-REAL、THIN trials，這些實驗的結果發現，SGLT-2 inhibitor可以降低心血管相關的併發症及死亡率，其中某些實驗結果也顯示此類藥物或許可以改善糖尿病腎臟病。
主题分类 醫藥衛生 > 基礎醫學
醫藥衛生 > 社會醫學
参考文献
  1. Kosiborod, M,Cavender, MA,Fu, AZ(2017).Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVDREAL study (comparative effectiveness of cardiovascular outcomes in new users of sodiumglucose cotransporter-2 inhibitors).Circulation,136,249-259.
  2. Lewis, EJ,Hunsicker, LG,Bain, RP,Rohde, RD(1993).The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.N Engl J Med,329,1456-1462.
  3. National Kidney Foundation. End stage renal disease in the United States, 2019. .
  4. Neal, B,Perkovic, V,Mahaffey, KW(2017).Canagliflozin and cardiovascular and renal events in type 2 diabetes.N Engl J Med,377,644-657.
  5. Perkovic, V,Jardine, MJ,Neal, B(2019).Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med,380,2295-2306.
  6. Toulis, KA,Willis, BH,Marshall, T(2017).All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, opencohort study in The Health Improvement Network database.J Clin Endocrinol Metab,102,1719-1725.
  7. Tsimihodimos, V,Filippatos, TD,Elisaf, MS(2018).SGLT2 inhibitors and the kidney: Effects and mechanisms.Diabetes Metab Syndr,12,1117-1123.
  8. UK Prospective Diabetes Study (UKPDS) Group(1998).Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).Lancet,352,837-853.
  9. Umanath, K,Lewis, JB(2018).Update on diabetic nephropathy: core curriculum 2018.Am J Kidney Dis,71,884-895.
  10. Zinman, B,Wanner, C,Lachin, JM(2015).Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med,373,2117-2128.
print cancel